

# INSIDE THIS ISSUE

---

## PG. 2

Human Disease Research

---

## PG. 3

Bioinformatics & Biotechnology

---

## PG. 4

Reviews & Book Chapters

Dear readers,

As the year draws to a close, we take pride in reflecting on the research accomplishments of 2024 and excited to present the 4th edition of our newsletter, showcasing a selection of the publications that have emerged from our Center this year.

We are grateful for the dedication and hard work of our researchers, whose passion for science drives our Center's mission forward.


We also extend our thanks to our research collaborators in Greece and all over the world, whose contributions and partnerships are invaluable to our success.

For a full list of the Center's 2024 publications please visit <https://www.fleming.gr/research/fleming-publications>

Here's to a wonderful holiday season and a new year filled with inspiration and joy!

Warmest wishes,  
*From all of us at the BSRC "Alexander Fleming" 🎄*








In 2024, our Center made significant strides in understanding the basis of chronic & genetic diseases and bringing us one step closer to their treatment. We discovered the first-in-class inhibitors for HYOU1, whose targeting offers new hope for modulating fibroblast activation and treating **chronic inflammatory and fibrotic disorders**. We also identified the regulatory role of Cyld in controlling synovial fibroblast hyperactivation in **rheumatoid arthritis** potentially paving the way for novel therapeutic strategies. Our research on **Crohn's disease** revealed the dominant pathogenic functions of IL-23, emphasizing its critical role in ileitis and suggesting more effective treatment approaches. Additionally, we uncovered the involvement of Cockayne syndrome B protein in transcription and chromatin dynamics, providing deeper insights into the molecular mechanisms underlying the **Cockayne Syndrome** severe progeroid disorder.

# Human Disease Research

## MEDICINAL CHEMISTRY & IN VIVO STUDIES




Papadopoulou et al. "Discovery of the First-in-Class Inhibitors of Hypoxia Up-Regulated Protein 1 (HYOU1) Suppressing Pathogenic Fibroblast Activation." *Angew Chem Int Ed Engl.* (2024).  
<https://doi.org/10.1002/anie.202319157>


Rinotas et al. "Cyld restrains the hyperactivation of synovial fibroblasts in inflammatory arthritis by regulating the TAK1/IKK2 signaling axis." *Cell Death Dis.* (2024).  
doi: [10.1038/s41419-024-06966-2](https://doi.org/10.1038/s41419-024-06966-2)


Iliopoulou et al. "IL-23 Exerts Dominant Pathogenic Functions in Crohn's Disease-Ileitis." *Mucosal Immunology* (2024).  
<https://doi.org/10.1016/j.mucimm.2024.05.008>

## REGULATORY (EPI)GENOMICS




Liakos et al. "Cockayne syndrome B protein is implicated in transcription and associated chromatin dynamics in homeostatic and genotoxic conditions." *Aging Cell* (2024).  
<https://onlinelibrary.wiley.com/doi/10.1111/ace1.14341>






Stylianaki et. al "Identification of two novel chemical classes of Autotaxin (ATX) inhibitors using Enalos Asclepios KNIME nodes." Bioorg Med Chem Lett. (2024). <https://doi.org/10.1016/j.bmcl.2024.129690>



# Bioinformatics & Biotechnology


Our bioinformatics and biotechnology research in 2024 led to groundbreaking discoveries. We identified two novel chemical classes of Autotaxin (ATX) inhibitors, potentially revolutionizing the treatment of **fibrotic diseases and cancer**. Our work with *Escherichia coli* unveiled a new strain of bacteria, SuptoxRNE22, capable of significantly enhancing membrane protein production, offering a valuable tool for **biotechnological applications**. Moreover, we discovered a highly stable carbonic anhydrase enzyme, CA-KR1, which shows promise for industrial CO<sub>2</sub> capture, presenting an eco-friendly solution to combat **global warming**.

## SYNTHETIC BIOLOGY





Vasilopoulou et al. "Escherichia coli strains with precise domain deletions in the ribonuclease RNase E can achieve greatly enhanced levels of membrane protein production." Protein Science. (2024). <https://doi.org/10.1002/pro.4864>

## ENVIRONMENTAL SCIENCE




Rigkos et al. "Biomimetic CO<sub>2</sub> Capture Unlocked through Enzyme Mining: Discovery of a Highly Thermo- and Alkali-Stable Carbonic Anhydrase." Environmental Science & Technology (2024). <https://doi.org/10.1021/acs.est.4c04291>




Konstantakopoulou C. and Verykokakis M. "Key functions of the transcription factor Bcl6 during T cell development" *Adv Exp Med Biol.* (2024). DOI: [10.1007/978-3-031-62731-6\\_4](https://doi.org/10.1007/978-3-031-62731-6_4)

Samiotaki et al. "Detection of Protein Tyrosine Phosphatase Interacting Partners by Mass Spectrometry" *Methods Mol Biol.* (2024). DOI: [10.1007/978-1-0716-3569-8\\_11](https://doi.org/10.1007/978-1-0716-3569-8_11)




## Reviews & Book Chapters

### NEUROSCIENCE



Atsoniou et al. "Drosophila Contributions towards Understanding Neurofibromatosis 1." *Cells.* (2024). <https://doi.org/10.3390/cells13080721>

### METAGENOMICS



Aplakidou et al. "Visualizing metagenomic and metatranscriptomic data: A comprehensive review" *Comput Struct Biotechnol J.* (2024). <https://doi.org/10.1016/j.csbj.2024.04.060>

Our reviews and book chapters in 2024 provided comprehensive insights into various fields. We explored the role of *Drosophila* in understanding **Neurofibromatosis 1**, shedding light on the disease's cellular mechanisms and potential therapeutic strategies. Our review on visualizing metagenomic and metatranscriptomic data highlighted advanced tools for effectively analyzing **complex biological datasets**. We also delved into the critical functions of the transcription factor **Bcl6 in T cell development**, enhancing our understanding of immune responses. Finally, we detailed methodologies for detecting protein tyrosine phosphatase interacting partners and contributing to the mapping of signaling pathways in health and disease using **mass spectrometry**.

